SynthesisBMC gastroenterology2026
Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) cancers, including pancreatic, gastric, esophageal, colorectal, and hepatocellular carcinoma (HCC), have high mortality rates. Despite advances in immune checkpoint inhibitors (ICIs), treatment outcomes remain variable. Identifying reliable biomarkers, such as the systemic immune-inflammation index (SII), which combines platelet, neutrophil, and lymphocyte counts, could help optimize treatment strategies. Biologically, an elevated SII is thought to indicate a dominance of pro-tumor inflammation and a suppressed adaptive immune response, thereby potentially dampening the therapeutic efficacy of ICIs.
methodsA systematic review was conducted of studies from Cochrane Library, Embase, and PubMed, published until August 15, 2025. This review was conducted in strict adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies involved GI cancer patients treated with ICIs, reported baseline or treatment SII data, and provided hazard ratios (HRs) for progression-free survival (PFS) or overall survival (OS). Exclusions included studies on non-GI cancers or incomplete data.
results28 studies with 4752 patients were included. High baseline SII levels were associated with worse OS and PFS in gastric cancer (OS: HR = 2.24, 95% CI: 1.84-2.72, I
conclusionSII is a promising, cost-effective prognostic biomarker for GI cancer patients receiving ICIs. Elevated baseline SII predicts poorer survival, particularly in gastric cancer, HCC, and esophageal cancer. These findings highlight the potential utility of SII in patient risk stratification and clinical decision-making, thereby supporting its integration into precision oncology strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.